Skip to main content
. 2001 Jul;8(4):718–723. doi: 10.1128/CDLI.8.4.718-723.2001

TABLE 2.

Validity of HpSA results in patients with suspected treatment failures or recurrences posttreatment using biopsy as the gold standard

Category % Sensitivity [95% CI] % Specificity [95% CI]
Treatment failures (1 mo posttreatment) 86 [42–99] (6/7) 33 [2–88] (1/3)
Recurrences (3, 6, or 9 mo posttreatment) 68 [44–86] (13/19) 100 [31–100] (3/3)
All treatment failures and recurrences (at any follow-up point up to 9 mo posttreatment) 73 [52–88] (19/26) 67 [24–94] (4/6)